Meggitt Training Systems, an industry-leading, turnkey provider of design, development, equipment and installation of military live-fire training ranges, will exhibit at the 2015 Levels of Fidelity annual conference in Walenstadt, Switzerland. From Oct. 19-21, 2015, Meggitt representatives will discuss the products and technologies that are bringing more and more international service outfits to choose Meggitt as a strategic partner.
The European operations of Monsanto, a global leader in sustainable agricultural solutions, have been ranked 24th in this year’s list of the Great Place to Work Institute’s Best Workplaces in Europe.
The Medicines Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued positive opinions recommending marketing authorization for three of its pipeline development candidates – KENGREXAL™ (cangrelor), ORBACTIV™ (oritavancin), and RAPLIXA™ (sealant powder). These positive opinion recommendations represent category firsts across three therapeutic areas:
The University of Colorado Boulder Leeds School of Business, which includes the well-regarded Business Research Division, and The Western Union Company (NYSE:WU), a leader in global payment services, today announced the release of a first-of-its-kind study that sheds new light on the positive impact of cross-border money transfer broadly and of Western Union services in particular.
MSD, known as Merck in the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed pembrolizumab, the company’s anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab-refractory advanced melanoma (n=540).1 At six months, the PFS rates for pembrolizumab were 34 percent at the 2 mg/kg dose (95% CI, 27-41) (n=180) and 38 percent at the 10 mg/kg dose (95% CI, 31-45) (n=181), compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The median duration of follow-up at the interim analysis was 10 months.1
Archer Daniels Midland Company (NYSE: ADM) today announced that it is acquiring WILD Flavors GmbH, giving ADM the ability to offer food and beverage companies a comprehensive suite of systems to enhance and improve their products.
Ecolab Inc., the global leader in water, hygiene and energy technologies and services, has launched Apex, a warewashing system that will provide the cleaning results restaurant and foodservice operators throughout Europe expect, while reducing water and energy use.
The fractional ownership leader, NetJets Europe, has today announced that it will be taking delivery of the Signature Series™ Challenger 350 aircraft from Bombardier Business Aircraft. The all new Challenger 350 will join the European fleet as an industry leading super-midsize aircraft in mid-2015, following the delivery this summer to NetJets US. The additional aircraft on order are scheduled to arrive over the next few years.
Executive Jet Management (Europe) has today announced that it has been issued with its personal Air Operating Certificate (AOC) and license. The company, with NetJets Europe’s support, has been working over recent months to develop an additional AOC specific to the management business.
In recognition of World TB Day 2014, Otsuka SA (Otsuka), in a global partnership with the International Union Against Tuberculosis and Lung Disease (The Union), today issued a call for nominations for its Young Innovator in TB Research Award, aimed at recognizing young scientists who have demonstrated a commitment to advancing innovative thinking in tuberculosis (TB) research.